Systematic ReviewResearchMedication Safety

Caffeine evidence for late-preterm hypoxemia remains limited to one small trial

The Cochrane database of systematic reviews (PubMed)Aug 20, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A Cochrane review found only one randomized trial of 132 late-preterm infants; caffeine may reduce intermittent hypoxemia episodes over one week, but the evidence was low certainty.

What NurseJet pulled from the source

The review found very low-certainty evidence for respiratory support, hospital stay, and adverse effects leading to treatment discontinuation, and low-certainty evidence of little to no difference in predischarge mortality. No eligible trial evaluated treatment of established hypoxemia, apnea, or respiratory insufficiency.

Why this matters for nurses

Pediatric and neonatal nurses administer prescribed methylxanthines and closely trend oxygenation and respiratory support. The review sets an important evidence boundary: a preliminary prevention signal should not be interpreted as proof of broader respiratory or long-term benefit in late-preterm infants.

Bedside takeaway

Treat the late-preterm caffeine signal as preliminary: one small trial suggests fewer hypoxemia episodes, while respiratory-support, safety, and long-term effects remain uncertain.

How This Applies in Practice

Use this when: Caring for a late-preterm infant who has a provider order for caffeine or another methylxanthine and requires respiratory-event surveillance.

On your shift

Confirm the documented indication, gestational-age context, dose, route, and monitoring schedule before administration.
Document hypoxemia, apnea, respiratory support, and treatment response using the unit's defined event criteria.
Escalate recurrent events or unexpected clinical changes through the neonatal or pediatric care pathway.

Keep in mind: The evidence is limited to prevention in one small trial and does not establish treatment benefit for an acute event. Follow neonatal facility policy, the medication protocol, and provider orders.

Key takeaways

The review included one New Zealand randomized trial involving 132 infants born at 34 0/7 to 36 6/7 weeks' gestation.
Caffeine may reduce intermittent hypoxemia episodes over one week, but this finding was based on low-certainty evidence.
Effects on respiratory support, length of stay, and treatment-stopping adverse effects remained very uncertain.
No study reported major neurodevelopmental disability or evaluated methylxanthines for treatment of established hypoxemia, apnea, or respiratory insufficiency.

Practice implications

When caring for a late-preterm infant receiving a prescribed methylxanthine, confirm the documented indication and follow the ordered cardiorespiratory surveillance and medication-monitoring pathway. Record hypoxemia or apnea events consistently so the team can evaluate response without assuming benefit beyond the limited evidence.

Limitations & cautions

All conclusions came from one 132-infant trial. Every outcome was downgraded for serious or very serious imprecision, several outcomes also had risk-of-bias concerns, and no evidence addressed treatment of established respiratory problems or major neurodevelopmental disability.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

The Cochrane database of systematic reviews (PubMed)

The Cochrane database of systematic reviews (PubMed). Methylxanthines for the prevention or treatment of intermittent hypoxemia or respiratory insufficiency in late preterm infants.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42621780/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Renal failure (PubMed)Sep 7, 2026Research Article

A single-center retrospective cohort found that approximately one quarter of laboratory-defined acute kidney injury cases on internal medicine wards were not documented, particularly when maximal creatinine was lower.

Med-SurgAI summaryReview source

Research ArticleResearchQuality ImprovementAI summary · original source linked below

Among 161 adult hospitalizations meeting serum-creatinine criteria for acute kidney injury, 39 cases (24.2%) were undocumented. Length of stay and in-hospital mortality did not differ significantly by documentation status.

Key takeaways

In the 149 hospitalizations with a demonstrable creatinine change, 33 cases (22.1%) were undocumented.
Higher maximal creatinine was associated with lower adjusted odds of underdocumentation.
The study did not test whether a detection or documentation intervention improves care or outcomes.

Why this matters on shift

A smaller creatinine rise may receive less attention even when it meets the study's laboratory definition of acute kidney injury, which can affect how renal risk is communicated across the inpatient team.

Bedside takeaway

Trend ordered renal-function results and communicate clinically important changes through local escalation and documentation workflows.

Nursing implications

Trend ordered renal-function results and communicate clinically important changes through the care team according to local escalation and documentation workflows.

Limitations & cautions

Abstract-only summary. This was a retrospective, single-center study of 161 hospitalizations; urine-output criteria and reliable preadmission creatinine values were unavailable, and the reference creatinine method may affect case classification.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Renal failure (PubMed). Underdocumentation of laboratory-defined acute kidney injury in internal medicine wards: a retrospective cohort study.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of midwifery & women's health (PubMed)Sep 7, 2026Research Article

A retrospective analysis of US natality data found no statistically significant yearly difference in neonatal mortality between freestanding birth centers and hospitals among term, singleton, vertex births without major medical risk factors from 2015 through 2024.

L&D / OB PedsAI summaryReview source

Research ArticleResearchPatient EducationAI summary · original source linked below

Adjusted neonatal-mortality odds for freestanding birth centers fluctuated around 1.0 across the 10-year study period. No individual year showed a statistically significant difference from hospital births, including 2020 and 2021 when birth-center volume increased.

Key takeaways

The analysis was restricted to births meeting selected low-risk criteria.
The study found no evidence that higher birth-center use during the pandemic years increased neonatal mortality.
The observational design cannot establish that birth setting itself caused the mortality pattern.

Why this matters on shift

The findings add national outcome data for counseling and systems planning around freestanding birth-center care for appropriately selected low-risk pregnancies.

Bedside takeaway

Apply local eligibility, surveillance, escalation, and transfer protocols when caring for planned low-risk birth-center patients.

Nursing implications

Keep eligibility, surveillance, escalation, and transfer decisions anchored to local birth-center criteria and maternal-newborn protocols.

Limitations & cautions

Abstract-only summary. The study used retrospective vital-record data, was limited to selected low-risk births, and cannot exclude residual differences between people who delivered in birth centers and hospitals.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of midwifery & women's health (PubMed). Neonatal Mortality Risk Among Births in Freestanding Birth Centers, 2015 to 2024.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Pediatric emergency care (PubMed)Sep 7, 2026Research Article

A double-blind randomized trial found no reduction in vomiting or faster oral tolerance with intravenous pantoprazole versus placebo in children with acute gastroenteritis and persistent vomiting after ondansetron.

Peds EmergencyAI summaryReview source

Research ArticleResearchMedication SafetyAI summary · original source linked below

The trial randomized 100 children. Vomiting episodes and oral tolerance at 6 and 12 hours did not differ significantly, while median hospital stay was 2 days with pantoprazole and 1 day with placebo.

Key takeaways

The median participant age was 14 months, and 67% of participants were male.
Oral tolerance at 12 hours was 86% in both groups.
The longer stay associated with pantoprazole requires cautious interpretation because this was a single-center trial.

Why this matters on shift

The trial does not support empiric intravenous proton-pump inhibition for persistent vomiting in pediatric acute gastroenteritis after ondansetron.

Bedside takeaway

Clarify the indication for empiric acid suppression and keep hydration and oral-tolerance assessment central to care.

Nursing implications

Prioritize the ordered hydration and oral-tolerance plan, document ongoing emesis, and clarify the indication before administering empiric acid suppression.

Limitations & cautions

Abstract-only summary. This was a single-center study of 100 children in Tehran, and the abstract does not describe adverse events or explain why hospitalization was longer in the pantoprazole group.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Pediatric emergency care (PubMed). Effect of Intravenous Pantoprazole on Clinical Outcomes in Pediatric Acute Gastroenteritis: A Placebo-Controlled RCT.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

One in four laboratory-defined AKI cases went undocumented on medicine wards

Low-risk birth-center births showed no higher neonatal mortality in a 10-year analysis

IV pantoprazole did not improve vomiting or oral tolerance in pediatric gastroenteritis